Tamra Sami

Perth

Staff Writer at BioWorld

Staff Writer at Clarivate

Science writer, editor, publication manager with product development, Asia and emerging markets expertise.

Featured in: Favicon

bioworld.com Favicon

usnews.com Favicon

endpts.com Favicon

biopharmadive.com Favicon

centerwatch.com Favicon

biocentury.com Favicon

pharmamedtechbi.com

Articles

Qilu nabs China rights to Minghui’s B7-H3 ADC for up to $186M

3 days ago | bioworld.com | Tamra Sami

Qilu nabs China rights to Minghui’s B7-H3 ADC for up to $186MMinghui Pharmaceutical Ltd. is out-licensing its antibody-drug conjugate (ADC) MHB-088C to Qilu Pharmaceutical Co. Ltd. for China rights for up to ¥1.345 billion (US$186.44 million). Under terms of the deal, Qilu gains rights to develop and manufacture the ADC in greater China, including mainland China, Hong Kong, Macau, and Taiwan. BioWorld Deals and M&A Cancer Antibody-drug conjugate Asia-Pacific China
Cynata’s MSC cells show positive results across variety of delivery systems

6 days ago | bioworld.com | Tamra Sami

Home » Cynata’s MSC cells show positive results across variety of delivery systems BioWorld briefs for May 8, 2025. BioWorld MedTech briefs for May 8, 2025. The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the... Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
Oncosil’s brachytherapy device outperforms SBRT in pancreatic cancer

1 week ago | bioworld.com | Tamra Sami

Home » Oncosil’s brachytherapy device outperforms SBRT in pancreatic cancer BioWorld briefs for May 8, 2025. BioWorld MedTech briefs for May 8, 2025. The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the... A metabolic vulnerability of pancreatic ductal adenocarcinoma (PDAC) could be used to address this type of cancer that often resists treatments. Scientists at the...
Innovent’s IBI-302 meets phase II endpoints in neovascular AMD

1 week ago | bioworld.com | Tamra Sami

Innovent’s IBI-302 meets phase II endpoints in neovascular AMDInnovent Biologics Inc.’s efdamrofusp alfa (IBI-302) met the primary endpoint in phase II, showing a gain of 10 or more letters in visual acuity from baseline at one year in Chinese patients with neovascular age-related macular degeneration. BioWorld BioWorld Asia Ocular Monoclonal antibody Asia-Pacific China
Australia follows Canadian lead; Labor win a sharp rebuke to Trump

1 week ago | bioworld.com | Tamra Sami

Home » Australia follows Canadian lead; Labor win a sharp rebuke to Trump BioWorld briefs for May 5, 2025. BioWorld MedTech briefs for May 5, 2025. The U.S. FDA has accepted the NDA for an oral formulation of Novo Nordisk A/S’s Wegovy (semaglutide) in treating obesity. If approved, the daily pill will be the... The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
AACR 2025: D3 Bio, Immvira present solid tumor, brain cancer data

1 week ago | bioworld.com | Tamra Sami

AACR 2025: D3 Bio, Immvira present solid tumor, brain cancer dataShanghai-based D3 Bio (Wuxi) Co. Ltd. showed positive results for its lead candidate, next-generation KRAS G12C inhibitor, D3S-001, also known as elisrasib, in patients with KRAS G12C mutation cancers, including patients previously treated with first-generation KRAS G12C inhibitors. Presented at the American Association for Cancer Research (AACR 2025) meeting on April 29, the data were simultaneously published in Nature Medicine.
Immutep’s efti shows strong survival data in head and neck cancer

1 week ago | bioworld.com | Tamra Sami

Immutep’s efti shows strong survival data in head and neck cancerImmutep Ltd. announced strong median overall survival of 17.6 months in cohort B of the TACTI-003 (Keynote-PNC-34) phase IIb trial that evaluated eftilagimod alfa in combination with Merck & Co.’s Keytruda (pembrolizumab) as first-line therapy in recurrent/metastatic head and neck squamous cell carcinoma in patients with PD-L1 expression below 1. BioWorld Clinical Cancer Immuno-oncology Asia-Pacific Australia
Australia follows Canadian lead; Labor win a sharp rebuke to Trump

1 week ago | bioworld.com | Tamra Sami

Home » Australia follows Canadian lead; Labor win a sharp rebuke to Trump BioWorld briefs for May 2, 2025. BioWorld MedTech briefs for May 2, 2025. Physicians aren’t the only ones who see prior authorization (PA) practices as a significant problem, but John Brooks, deputy administrator at CMS, told a med tech... The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
Dimerix strikes $601M Amicus deal for kidney disease drug DMX-200

2 weeks ago | bioworld.com | Tamra Sami

Home » Dimerix strikes $601M Amicus deal for kidney disease drug DMX-200 BioWorld briefs for April 30, 2025. BioWorld MedTech briefs for April 30, 2025. The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the... KRAS mutations are found in more than 90% of pancreatic cancer cases, with the G12D variant being the most prevalent. BioWorld Asia briefs for April 22, 2025
AACR 2025: D3 Bio, Immvira present solid tumor, brain cancer data

2 weeks ago | bioworld.com | Tamra Sami

AACR 2025: D3 Bio, Immvira present solid tumor, brain cancer dataShanghai-based D3 Bio (Wuxi) Co. Ltd. showed positive results for its lead candidate, next-generation KRAS G12C inhibitor, D3S-001, also known as elisrasib, in patients with KRAS G12C mutation cancers, including patients previously treated with first-generation KRAS G12C inhibitors. Presented at the American Association for Cancer Research (AACR 2025) meeting on April 29, the data were simultaneously published in Nature Medicine.